Deceleration of the neurodegenerative phenotype in pyroglutamate-Aβ accumulating transgenic mice by oral treatment with the Aβ oligomer eliminating compound RD2
Alzheimer's disease, a multifactorial incurable disorder, is mainly characterised by progressive neurodegeneration, extracellular accumulation of amyloid-β protein (Aβ), and intracellular aggregation of hyperphosphorylated tau protein. During the last years, Aβ oligomers have been claimed to be...
Main Authors: | Sarah Schemmert, Elena Schartmann, Dominik Honold, Christian Zafiu, Tamar Ziehm, Karl-Josef Langen, Nadim Joni Shah, Janine Kutzsche, Antje Willuweit, Dieter Willbold |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-04-01
|
Series: | Neurobiology of Disease |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0969996118307320 |
Similar Items
-
Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer’s Disease
by: Janine Kutzsche, et al.
Published: (2017-10-01) -
Do We Need Anti-Prion Compounds to Treat Alzheimer’s Disease?
by: Dieter Willbold, et al.
Published: (2019-06-01) -
The Toxicity and Polymorphism of β-Amyloid Oligomers
by: Ya-ru Huang, et al.
Published: (2020-06-01) -
β-amyloid oligomers in aging and Alzheimer's disease
by: Kathleen R. Zahs, et al.
Published: (2013-07-01) -
Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease
by: Barbara Mroczko, et al.
Published: (2018-06-01)